Clinical trials: Mild Persistent Asthma
Asthma
Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma
The purpose of this study is to study the safety and tolerability in adolescent and adult subjects with intermittent or mild to moderate persistent asthma.
- Trial name
- NCT01137565
- Testing
- AMG 853
- Volunteers
- 23 people
- Sponsor
- Amgen
Asthma
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
- Trial name
- NCT00044811
- Testing
- Fexofenadine
- Where
- 7 sites in United States, Costa Rica and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Healthy, Asthma
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
The purpose of this study is to investigate the cytokine levels in nasal lavage and gene expression in nasal scraping following a single nasal dose of JNJ-43260295 in healthy participants, and in atopic mild to mild-persistent…
- Trial name
- NCT02243189
- Testing
- JNJ-43260295, Nasal Allergen Challenge
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Mild to Moderate Persistent Asthma
OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma
This will be a double blind, randomised, 4 arm, parallel group, placebo controlled study of three dose levels of OC000459 tablets in patients with asthma controlled by beta agonist drugs alone.
- Trial name
- NCT00890877
- Where
- 6 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 480 people
- Sponsor
- Oxagen Ltd
Mild to Moderate Persistent Asthma
Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.
This study aims to find out if AES ( Activation Energy Serum) , a blend of natural minerals , is effective and safe for the treatment of asthma if taken for 4 weeks .
- Trial name
- NCT01939951
- Testing
- Activation Energy Serum
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- California Allergy and Asthma Medical Group, Inc.
Asthma
Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma
The purpose of this study is to compare the effects of Fluticasone/ salmeterol combination and double the dose of fluticasone on airway hyper-responsiveness to methacholine in a randomised, double blind, double dummy, cross-over…
- Trial name
- CLE001 (NCT00830505)
- Testing
- fluticasone/salmeterol, fluticasone
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- University of Dundee
Asthma
Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Children with mild persistent asthma that have asthma symptoms once or twice a week and use a daily controller, while children with mild intermittent asthma rarely have asthma symptoms and do not use a daily controller.
- Trial name
- NCT01520688
- Testing
- Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- West Penn Allegheny Health System
Asthma
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose…
- Trial name
- A006-B3 (NCT02210806)
- Testing
- A006 DPI, Proventil® MDI
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Fenzian Asthma Multicenter Outcomes Study
The purpose of this study is to investigate the effects of Fenzian™ treatment on symptoms (such as shortness of breath), lung function (how well the lungs work), and albuterol/salbutamol (rescue medication) use in people with…
- Trial name
- FAMOUS (NCT00784758)
- Testing
- Fenzian Device
- Where
- 6 sites in United States, South Africa and 1 more
- Volunteers
- 81 people
- Sponsor
- University of California, Los Angeles
Persistent Asthma
Efficacy, Safety, and Pharmacokinetics of QAW039
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
- Trial name
- NCT01253603
- Testing
- QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
- Trial name
- NCT03188120
- Testing
- Spiriva Respimat
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.
To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174720
- Testing
- Ciclesonide (XRP1526)
- Where
- 11 sites in United States, Brazil and 9 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Asthma, Bronchial
A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
A study to evaluate MK0476 and Fluticasone to control asthma in patients with mild persistent asthma.
- Trial name
- NCT00489346
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 1 Year, Comparator : fluticasone propionate / Duration of Treatment: 1 Year
- Volunteers
- 994 people
- Sponsor
- Organon and Co
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Mild Persistent Asthma
Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
Aim of the study is to investigate the short-term growth in children with asthma aged 5-11 years in treatment with fluticasone propionate / formoterol spray (flutiform®) 200/20 micrograms per day
- Trial name
- NCT02063139
- Testing
- Flutiform 50/5 ug (2 puffs bid) pMDI, Fluticasone 50 ug (2puffs bid) pMDI, Beclometasone Autohaler 50 ug (2 puffs bid)
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Mundipharma Research Limited
Drug Safety
A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma
The purpose of this study is to assess the safety and tolerability of MDT-637, when inhaled by subjects with Intermittent, or Mild-to-Moderate Persistent, Asthma.
- Trial name
- NCT01556607
- Testing
- MDT-637
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- MicroDose Therapeutx, Inc
Mild Persistent Asthma
Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.
This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.
- Trial name
- NCT01581710
- Volunteers
- 32 people
- Sponsor
- CHA University
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium compared to placebo over 12 week treatment period.
- Trial name
- NCT01316380
- Testing
- tiotropium 2.5 mcg, tiotropium 5 mcg
- Where
- 62 sites in Argentina, Austria and 10 more
- Volunteers
- 465 people
- Sponsor
- Boehringer Ingelheim